



PATENT  
Customer No. 22,852  
Attorney Docket No. 8717.0010

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
David J. KYLE ) Group Art Unit: Not yet assigned  
)  
Application No.: 10/654,985 ) Examiner: Not yet assigned  
)  
Filed: September 5, 2003 )  
)  
For: DELIVERY OF DISEASE )  
CONTROL IN AQUACULTURE )  
AND AGRICULTURE USING )  
MICROBES CONTAINING )  
BIOACTIVE PROTEINS )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign patent documents and manuscripts, and a copy of copending application WO 02/076391 are enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 14, 2004


By   
Kenneth J. Meyers  
Reg. No. 25,146

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	8717.0010	Appln. No.	10/654,985
Applicant	David J. Kyle		
Filing Date	September 5, 2003	Group:	Not Yet Assigned



## U.S. PATENT DOCUMENTS


Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,270,175	Dec. 14, 1993	Moll			July 12, 1991
	5,830,463	Nov. 3, 1998	Duke et al.			Nov. 15, 1994
	5,977,437	Nov. 2, 1999	Villand et al.			Apr. 7, 1994
	6,027,900	Feb. 22, 2000	Allnutt et al.			Apr. 11, 1997
	6,156,517	Dec. 5, 2000	Mayfield			Jan. 16, 1998
	6,294,653	Sep. 25, 2001	Mayfield			Jul. 10, 2000
	US 2003/0072772	N/A	Vakharia			Aug. 12, 2002
	5,661,017	Aug. 26, 1997	Dunahay et al.			Mar. 15, 1995
	5,681,557	Oct. 28, 1997	Grabstein et al.			May 15, 1995
	6,100,388	Aug. 8, 2000	Casas et al.			Mar. 16, 1998
	6,399,074	Jun. 4, 2002	Roland			Jul. 24, 1998
	6,462,027	Oct. 8, 2002	Poet et al.			Jul. 6, 1999
	US 2002/0090376	N/A	Kaniga et al.			Mar. 31, 1997
	US 2002/0102692	N/A	Lei			Jun. 25, 1998

## FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 02 076391	Oct. 3, 2002	PCT			no
WO 01/96871	Dec. 20, 2001	PCT			no
WO 01/98335	Dec. 27, 2001	PCT			no
WO 02/15721	Feb. 28, 2002	PCT			no (English Abstract)
WO 90/07578	Jul. 12, 1990	PCT			no
WO 95/35389	Dec. 28, 1995	PCT			no
WO 97/14806	Apr. 24, 1997	PCT			no

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	8717.0010	Appln. No.	10/654,985
Applicant	David J. Kyle		
Filing Date	September 5, 2003	Group:	Not Yet Assigned



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH (1998) A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol., vol. 16, pp. 934-938.
	Arakawa T, Yu J, Langridge WH (1999) Food Plant-Delivered Cholera Toxin B Subunit for Vaccination and Immunotolerization. Adv Exp Med Biol., vol. 464, pp. 161-178.
	Arntzen CJ (1998) Pharmaceutical foodstuffs--oral immunization with transgenic plants. Nat Med vol. 4, pp. 502-503.
	Burgess, J. Grant et al., (1993) Expression of Yellow Tail ( <i>Seriola Quinqueradiata</i> ) Fish Growth Hormone cDNA in the Marine Photosynthetic Bacterium Rhodobacter SP NKPB 0021, Biotechnology Letters, vol. 15, pp. 111-114.
	Kim, DH et al. (2002) Stable Integration and Functional Expression of Flounder Growth Hormone Gene in Transformed Microalga, Chlorella ellipsoidea. Marine Biotechnol (NY), vol. 4, pp. 63-73.
	Cregg JM, Cereghino JL, Shi J, Higgins DR (2000) Recombinant Protein Expression in Pichia pastoris. Mol Biotechnol., vol. 16, pp. 23-52.
	Leong, J.C., et al. (1997) Fish Vaccine Antigens Produced or Delivered by Recombinant DNA Technologies, Dev Biol Stand. Basel, Karger, vol. 90, pp. 267-277.
	Maassen CB et al. (2000) Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine, vol. 18, pp. 2613-2623.
	Mayfield, S., et al., (2001) Expression and assembly of a fully active antibody in algae. Proc. Natl. Acad. Sc., vol. 100, pp. 438-442.
	Richter L, Mason HS, Arntzen CJ (1996) Transgenic Plants Created for Oral Immunization Against Diarrheal Diseases, J Travel Med., vol. 3, pp. 52-56.
	Seto, Akiro, et al., (1992) Production of Eicosapentaenoic Acid by a Marine Microalgae and Its Commercial Utilization for Aquaculture, Ind. App. Single Cell Oils, chap. 12, pp. 219-234.
	Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ (1998) Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med., vol. 4, pp. 607-609.
	Tuse, Daniel, (1984) Single-Cell Protein: Current Status and Future Prospects. Critical Reviews in Food Science and Nutrition, vol. 19, pp. 273-325.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce